Resverlogix Corp. (RVXCF)

[noretreat]

Nice. (the link may not work)


November 15, 2017
Initiating Coverage: Resverlogix Corp. (RVX-T)
The New Doctor Is In. First Prescription Is A Full Dose of Resverlogix: C$8.55
12 Month Target: $8.55
Rating: BUY
CLICK HERE TO VIEW FULL REPORT

<C2928E8CA48E48F2B7401720B6478104.png>
The Canadian biotechnology sector is primed for a big turnaround. As Beacon's new analyst, I have had the opportunity to conduct a thorough environmental scan of the industry, and have created a "watch-list" of undervalued Canadian companies, whose science is innovative, coupled with impressive market potential and stellar management teams.

Epigenetics and Bromodomain Extra-Terminal (BET) inhibition are among the hottest fields in the global biotechnology sector with significant upside potential. Epigenetics is the field of medicine where the re-engineering of the environment impacts the final genetic product. When BET inhibition targets the right proteins in a diseased state, this has dramatic impact for affected patients, their Quality of Life, and life span.

Resverlogix Corp. has developed a proprietary platform to address epigenetics and BET inhibition in cardiovascular disease (CVD), chronic kidney disease (CKD), as well as orphan diseases impacted by Complement biology.

After taking a deep dive in Canadian biotech, we have concluded that Resverlogix may be one of the most undervalued biotech companies in Canada.

We are initiating coverage of Resverlogix with a Buy rating and C$8.55 target price based on the risk-adjusted NPV of its two initial disease states, CVD & CKD.
<C2928E8CA48E48F2B7401720B6478104.png>